MitoLab, Department of Life Sciences, University of Coimbra, 3000 Coimbra, Portugal.
MitoLab, Mitochondria, Metabolism and Disease Group, Center for Neurosciences and Cell Biology, Faculdade de Medicina, University of Coimbra, 3000 Coimbra, Portugal.
Cells. 2022 Feb 16;11(4):688. doi: 10.3390/cells11040688.
Hepatic ischemia reperfusion injury (HIRI) is a major hurdle in many clinical scenarios, including liver resection and transplantation. Various studies and countless surgical events have led to the observation of a strong correlation between HIRI induced by liver transplantation and early allograft-dysfunction development. The detrimental impact of HIRI has driven the pursuit of new ways to alleviate its adverse effects. At the core of HIRI lies mitochondrial dysfunction. Various studies, from both animal models and in clinical settings, have clearly shown that mitochondrial function is severely hampered by HIRI and that its preservation or restoration is a key indicator of successful organ recovery. Several strategies have been thus implemented throughout the years, targeting mitochondrial function. This work briefly discusses some the most utilized approaches, ranging from surgical practices to pharmacological interventions and highlights how novel strategies can be investigated and implemented by intricately discussing the way mitochondrial function is affected by HIRI.
肝缺血再灌注损伤(HIRI)是许多临床情况下的主要障碍,包括肝切除术和肝移植。各种研究和无数的手术事件都导致了观察到肝移植引起的 HIRI 与早期移植物功能障碍的发展之间存在很强的相关性。HIRI 的有害影响促使人们寻求新的方法来减轻其不良影响。HIRI 的核心是线粒体功能障碍。从动物模型到临床环境的各种研究都清楚地表明,HIRI 严重阻碍了线粒体功能,其保存或恢复是成功器官恢复的关键指标。多年来,已经实施了几种针对线粒体功能的策略。这项工作简要讨论了一些最常用的方法,从手术实践到药物干预,并通过详细讨论线粒体功能如何受 HIRI 的影响来强调如何研究和实施新策略。